Clinical Trial Update: PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia [Phase 4]

View source ↗

Summary

A Phase 4 pilot safety study evaluating weekly 10 mg/kg doses of AmBisome (liposomal amphotericin B) as antifungal prophylaxis in patients undergoing allogeneic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: Gilead Sciences | Conditions: Leukemia | Phase 4 | Status: COMPLETED